Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PARP inhibitor resistance: the underlying mechanisms and clinical implications
He Li, Zhaoyi Liu, Nayiyuan Wu, et al.
Molecular Cancer (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 352

Showing 1-25 of 352 citing articles:

Therapeutic developments in pancreatic cancer
Zilun Hu, Eileen M. O’Reilly
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 21, Iss. 1, pp. 7-24
Closed Access | Times Cited: 128
DNA damage response revisited: the p53 family and its regulators provide endless cancer therapy opportunities
Yasser Abuetabh, Hong Wu, Chengsen Chai, et al.
Experimental & Molecular Medicine (2022) Vol. 54, Iss. 10, pp. 1658-1669
Open Access | Times Cited: 103
Targeted Therapy and Mechanisms of Drug Resistance in Breast Cancer
Briana Kinnel, Santosh Kumar Singh, Gabriela Oprea‐Ilies, et al.
Cancers (2023) Vol. 15, Iss. 4, pp. 1320-1320
Open Access | Times Cited: 76
Cell cycle checkpoints and beyond: Exploiting the ATR/CHK1/WEE1 pathway for the treatment of PARP inhibitor–resistant cancer
Nitasha Gupta, Tzu‐Ting Huang, Sachi Horibata, et al.
Pharmacological Research (2022) Vol. 178, pp. 106162-106162
Open Access | Times Cited: 75
Cold and hot tumors: from molecular mechanisms to targeted therapy
Bo Wu, Bo Zhang, Bowen Li, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 39
Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells
Pankaj Garg, Jyoti Malhotra, Prakash Kulkarni, et al.
Cancers (2024) Vol. 16, Iss. 13, pp. 2478-2478
Open Access | Times Cited: 33
Recent advancements in nanoconstructs for the theranostics applications for triple negative breast cancer
Ashutosh Gupta, Kumar Nishchaya, Moumita Saha, et al.
Journal of Drug Delivery Science and Technology (2024) Vol. 93, pp. 105401-105401
Open Access | Times Cited: 19
Tumour mutational burden: clinical utility, challenges and emerging improvements
Jan Budczies, Daniel Kazdal, Michael Menzel, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 10, pp. 725-742
Closed Access | Times Cited: 18
Design, synthesis and biological evaluation of dual CDK9/PARP inhibitors for the treatment of cancer
Jindi Huang, Ya He, Sumeng Chen, et al.
European Journal of Medicinal Chemistry (2025) Vol. 287, pp. 117367-117367
Closed Access | Times Cited: 2
Development of synthetic lethality in cancer: molecular and cellular classification
Shijie Li, Win Topatana, Sarun Juengpanich, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 78
Exploiting synthetic lethality to target BRCA1/2-deficient tumors: where we stand
Parasvi S. Patel, Arash Algouneh, Razqallah Hakem
Oncogene (2021) Vol. 40, Iss. 17, pp. 3001-3014
Closed Access | Times Cited: 65
Homologous recombination proficiency in ovarian and breast cancer patients
Justin F. Creeden, Nisha S. Nanavaty, Katelyn R. Einloth, et al.
BMC Cancer (2021) Vol. 21, Iss. 1
Open Access | Times Cited: 63
Genetic Aberrations of DNA Repair Pathways in Prostate Cancer: Translation to the Clinic
Aruni Ghose, Michele Moschetta, George Pappas–Gogos, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 18, pp. 9783-9783
Open Access | Times Cited: 56
Mechanisms of Drug Resistance in Ovarian Cancer and Associated Gene Targets
Kharimat Lora Alatise, Samantha Gardner, Angela Alexander-Bryant
Cancers (2022) Vol. 14, Iss. 24, pp. 6246-6246
Open Access | Times Cited: 48
PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers
Linjie Luo, Khandan Keyomarsi
Expert Opinion on Investigational Drugs (2022) Vol. 31, Iss. 6, pp. 607-631
Open Access | Times Cited: 46
PARP1 proximity proteomics reveals interaction partners at stressed replication forks
Thorsten Mosler, H. Irem Baymaz, Justus F. Gräf, et al.
Nucleic Acids Research (2022) Vol. 50, Iss. 20, pp. 11600-11618
Open Access | Times Cited: 41
Immune-based combination therapy to convert immunologically cold tumors into hot tumors: an update and new insights
Jiaojiao Ni, Zizhen Zhang, Ming-jie Ge, et al.
Acta Pharmacologica Sinica (2022) Vol. 44, Iss. 2, pp. 288-307
Open Access | Times Cited: 39
Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA–Associated Pancreatic Cancer in the Clinical and Preclinical Setting
Chani Stossel, Maria Raitses‐Gurevich, Dikla Atias, et al.
Cancer Discovery (2023) Vol. 13, Iss. 8, pp. 1826-1843
Open Access | Times Cited: 29
Therapeutic strategies of dual-target small molecules to overcome drug resistance in cancer therapy
Jing Ye, Junhao Wu, Bo Liu
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1878, Iss. 3, pp. 188866-188866
Closed Access | Times Cited: 27
Poly (ADP-ribose) polymerase inhibitors (PARPi) in ovarian cancer: lessons learned and future directions
Giuseppe Caruso, Federica Tomao, Gabriella Parma, et al.
International Journal of Gynecological Cancer (2023) Vol. 33, Iss. 4, pp. 431-443
Open Access | Times Cited: 27
Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study
Jennifer K. Litton, J. Thaddeus Beck, Jason M. Jones, et al.
The Oncologist (2023) Vol. 28, Iss. 10, pp. 845-855
Open Access | Times Cited: 25
How BRCA and homologous recombination deficiency change therapeutic strategies in ovarian cancer: a review of literature
Martina Arcieri, Veronica Tius, Claudia Andreetta, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 15
BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1-Deficient Cancers
Guang Lei, Chao Mao, Amber D. Horbath, et al.
Cancer Discovery (2024) Vol. 14, Iss. 8, pp. 1476-1495
Closed Access | Times Cited: 15
A systematic analysis of the landscape of synthetic lethality-driven precision oncology
Alejandro A. Schäffer, Youngmin Chung, Ashwin V. Kammula, et al.
Med (2024) Vol. 5, Iss. 1, pp. 73-89.e9
Open Access | Times Cited: 11
PARP Inhibitors in Breast Cancer: a Short Communication
Gordon R. Daly, Maen Monketh Alrawashdeh, Jason McGrath, et al.
Current Oncology Reports (2024) Vol. 26, Iss. 2, pp. 103-113
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top